Biogen Inc. (NASDAQ:BIIB) – Equities researchers at Oppenheimer Holdings issued their FY2017 earnings estimates for Biogen in a research report issued on Wednesday. Oppenheimer Holdings analyst J. Olson expects that the biotechnology company will earn $21.97 per share for the year. Oppenheimer Holdings has a “Outperform” rating and a $350.00 price target on the stock. Oppenheimer Holdings also issued estimates for Biogen’s Q4 2017 earnings at $5.42 EPS, FY2018 earnings at $23.53 EPS, FY2019 earnings at $24.68 EPS and FY2020 earnings at $26.35 EPS.
Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Tuesday, October 24th. The biotechnology company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.70 by $0.61. The business had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. Biogen had a return on equity of 38.51% and a net margin of 29.44%. Biogen’s revenue was up 4.1% compared to the same quarter last year. During the same period last year, the firm posted $5.19 earnings per share.
TRADEMARK VIOLATION WARNING: “Oppenheimer Holdings Weighs in on Biogen Inc.’s FY2017 Earnings (BIIB)” was posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.truebluetribune.com/2017/11/14/oppenheimer-holdings-weighs-in-on-biogen-inc-s-fy2017-earnings-biib.html.
BIIB has been the topic of a number of other reports. UBS AG reissued a “neutral” rating and set a $285.00 price target (up from $270.00) on shares of Biogen in a research note on Wednesday, July 26th. Mizuho set a $400.00 price target on Biogen and gave the company a “buy” rating in a research note on Monday. Goldman Sachs Group, Inc. (The) raised Biogen from a “buy” rating to a “conviction-buy” rating and set a $338.00 price target on the stock in a research note on Wednesday, August 16th. Vetr lowered Biogen from a “buy” rating to a “hold” rating and set a $316.82 price target on the stock. in a research note on Monday, September 4th. Finally, Morgan Stanley raised Biogen from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $311.00 to $375.00 in a research note on Thursday, October 5th. Twelve analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $341.89.
Shares of Biogen (NASDAQ:BIIB) opened at $315.71 on Monday. The firm has a market capitalization of $65,650.89, a PE ratio of 14.38, a P/E/G ratio of 1.94 and a beta of 0.72. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.19 and a quick ratio of 1.90. Biogen has a 12 month low of $244.28 and a 12 month high of $348.84.
A number of hedge funds have recently bought and sold shares of the business. Guardian Life Insurance Co. of America boosted its position in Biogen by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 839 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 6 shares during the last quarter. Carroll Financial Associates Inc. boosted its position in Biogen by 1.2% in the second quarter. Carroll Financial Associates Inc. now owns 496 shares of the biotechnology company’s stock worth $134,000 after purchasing an additional 6 shares during the last quarter. RMB Capital Management LLC boosted its position in Biogen by 1.1% in the first quarter. RMB Capital Management LLC now owns 814 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 9 shares during the last quarter. New Amsterdam Partners LLC NY boosted its position in Biogen by 0.8% in the second quarter. New Amsterdam Partners LLC NY now owns 1,471 shares of the biotechnology company’s stock worth $399,000 after purchasing an additional 11 shares during the last quarter. Finally, Alta Capital Management LLC boosted its position in Biogen by 0.8% in the second quarter. Alta Capital Management LLC now owns 1,880 shares of the biotechnology company’s stock worth $510,000 after purchasing an additional 15 shares during the last quarter. 88.35% of the stock is currently owned by institutional investors and hedge funds.
Biogen Company Profile
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.